All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?

During the EHA2021 Virtual Congress, the GvHD Hub spoke with Eduardo Rodriguez Arboli, University of Seville, Seville, ES. We asked, Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?

Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?

In this video, Arboli reports on the results of a phase I study evaluating the safety and efficacy of glasdegib in patients with sclerotic chronic GvHD. He discusses tolerability, dosing, calcium channel blockers for muscle cramps, and the ongoing phase II study.

Share: